New Screening Method Detects Ovarian Cancer at Earlier Stage


Ovarian cancer, the fifth leading cause of cancer, is diagnosed in more than 20,000 women annually. Until recently, it has been difficult to diagnose at an early stage, but a new screening method for this disease could detect twice the amount than existing methods.

The risk of ovarian cancer (ROCA) detection strategies has commonly used single-biomarker thresholds to identify abnormality. Usha Menon, MD, and colleagues at the University of College London investigated the impact of serial biomarker change interpreted through a risk algorithm on cancer detection rates. Researchers used a different algorithm to interpret changing levels in women's annual serum cancer antigen 125 (CA125) protein, which has a better rate of detection than standard methods, according to a new study published in the Journal of Clinical Oncology.

In the United Kingdom Collaborative Trial of Ovarian Cancer Screening, 46,237 women, age 50 or older, underwent screening that measured (CA-125) to help determine the level of risk of ovarian cancer in each patient. Women were separated into three groups: normal risk (returned to annual screening), intermediate risk (repeat CA-125), and elevated risk (repeat CA-125 and transvaginal ultrasound).

The results were statistically significant. This new testing strategy gives a more accurate prediction of a woman's individual risk of developing cancer, compared to the conventional screening method which uses a fixed "cutoff" point for CA-125. The new method detected cancer in 86% of women with invasive epithelial ovarian cancer (iEOC), whereas the conventional test used in previous trials or in clinical practice would have identified fewer than half of these women (41% or 48%, respectively).

The researchers concluded that screening by using ROCA doubled the number of screen-detected iEOCs compared with a fixed cutoff. In the context of cancer screening, this is very exciting news for a hard-to-detect cancer.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content